From AAD 2025 to the Future: Advancements in Dermatology to Watch

A panelist discusses how the evolving landscape of atopic dermatitis treatment is moving toward a more personalized approach that carefully balances efficacy goals with safety considerations, incorporating new targeted therapies alongside traditional options while also expressing excitement about emerging research in dermatology including novel bispecific antibodies, microbiome-based interventions, and noninvasive diagnostic technologies that may revolutionize disease management in the coming years.

EP: 1.Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025

EP: 2.AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics

EP: 3.Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead

EP: 4.Ruxolitinib Cream and Atopic Dermatitis at AAD 2025

EP: 5.JAK Inhibitors vs Cytokine Inhibitors: AAD 2025 Findings on Infection Risks

Now Viewing

EP: 6.From AAD 2025 to the Future: Advancements in Dermatology to Watch

• How do you envision the treatment of atopic dermatitis evolving, particularly regarding the balance between efficacy, safety, and patient management?
• Please discuss any other data in the scope of dermatology released at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) that you find noteworthy to share with colleagues.
• Outside of AAD 2025, what ongoing research efforts are you most excited for in the treatment and management of dermatologic conditions? What can we look forward to through the end of the year and beyond?

Related Videos

Related Content

Advertisement

May 23rd 2025

5 Rare Disorders Named for Pioneering Female Scientists

Maggie L. Shaw

Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 22nd 2025

FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype

Brooke McCormick

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

Related Content

Advertisement

May 23rd 2025

5 Rare Disorders Named for Pioneering Female Scientists

Maggie L. Shaw

Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 22nd 2025

FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype

Brooke McCormick

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).